<code id='2E3D189F50'></code><style id='2E3D189F50'></style>
    • <acronym id='2E3D189F50'></acronym>
      <center id='2E3D189F50'><center id='2E3D189F50'><tfoot id='2E3D189F50'></tfoot></center><abbr id='2E3D189F50'><dir id='2E3D189F50'><tfoot id='2E3D189F50'></tfoot><noframes id='2E3D189F50'>

    • <optgroup id='2E3D189F50'><strike id='2E3D189F50'><sup id='2E3D189F50'></sup></strike><code id='2E3D189F50'></code></optgroup>
        1. <b id='2E3D189F50'><label id='2E3D189F50'><select id='2E3D189F50'><dt id='2E3D189F50'><span id='2E3D189F50'></span></dt></select></label></b><u id='2E3D189F50'></u>
          <i id='2E3D189F50'><strike id='2E3D189F50'><tt id='2E3D189F50'><pre id='2E3D189F50'></pre></tt></strike></i>

          Home / knowledge / comprehensive

          comprehensive


          comprehensive

          author:hotspot    Page View:649
          Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

          In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

          The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks. 

          advertisement

          “Oh, crap,” Secrist said to herself.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In